FDMT FY2025 EPS Estimate Lowered by Cantor Fitzgerald

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Stock analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.60) per share for the year, down from their previous forecast of ($3.40). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for 4D Molecular Therapeutics’ FY2026 earnings at ($2.87) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%.

Other analysts also recently issued reports about the company. Roth Capital reduced their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. The Goldman Sachs Group reduced their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Barclays dropped their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $30.40.

4D Molecular Therapeutics Price Performance

FDMT opened at $7.26 on Friday. The business has a fifty day simple moving average of $4.68 and a 200 day simple moving average of $4.14. The company has a market capitalization of $339.04 million, a PE ratio of -2.06 and a beta of 2.83. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $17.41.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth $39,000. Y Intercept Hong Kong Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth $41,000. Los Angeles Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth $42,000. Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth $42,000. Finally, AQR Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth $46,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.